551 related articles for article (PubMed ID: 19926549)
1. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
Fendri A; Masmoudi A; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Ghorbel A; Gargouri A; Mokdad-Gargouri R
Cancer Biol Ther; 2009 Mar; 8(5):444-51. PubMed ID: 19221469
[TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
6. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA
Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma.
Li J; El-Naggar A; Mao L
Cancer; 2005 Aug; 104(4):771-6. PubMed ID: 15959912
[TBL] [Abstract][Full Text] [Related]
9. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
10. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
Rastetter M; Schagdarsurengin U; Lahtz C; Fiedler E; Marsch WCh; Dammann R; Helmbold P
Histol Histopathol; 2007 Sep; 22(9):1005-15. PubMed ID: 17523078
[TBL] [Abstract][Full Text] [Related]
11. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
Safar AM; Spencer H; Su X; Coffey M; Cooney CA; Ratnasinghe LD; Hutchins LF; Fan CY
Clin Cancer Res; 2005 Jun; 11(12):4400-5. PubMed ID: 15958624
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas.
Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
Oral Oncol; 2011 Aug; 47(8):702-8. PubMed ID: 21697000
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
[TBL] [Abstract][Full Text] [Related]
16. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
17. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
18. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer.
Zhang J; Yu XL; Zheng GF; Zhao F
Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950
[TBL] [Abstract][Full Text] [Related]
19. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Takahashi N; Shimazaki Y; Motoyama T
Cancer Sci; 2003 Jul; 94(7):589-92. PubMed ID: 12841866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
